1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
WSI Co., Ltd.

WSI Co., Ltd.

KKRX:299170
1,201.00
KRW
-43.00
(-3.46%)
-28.01EPS
56.91BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
5,478.38
1,077.88
948.45
900.48
1,030.41
1,350.52
1,509.8
1,260.22
Basic EPS, GAAP
-12
814.47
-67
245
145
96
44
-106
-19.23
Free Cash Flow per Basic Share
-21.36
415.36
-15.12
75.14
-192.14
-325.31
217.71
60.14
88.66
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1,924.47
2,853.82
851.15
1,105.16
1,258.86
1,339.49
1,379.78
1,436.3
1,465.35
Tangible Book Value per Share
1,924.47
2,637.05
835.4
1,078.46
1,231.98
1,308.28
884.61
1,092.67
1,129.47
Basic Weighted Avg Shares
2
4
24
29
30
30
30
34
40
Sales/Revenue/Turnover
- -
23,721
26,386
27,776
27,129
30,877
40,411
51,706
50,769
Operating Margin (%)
- -
19.42
21.31
21.63
13.58
10.83
9.53
7.57
5.14
Depreciation Expense
- -
215
277
338
432
639
1,263
1,927
2,030
Net Income, GAAP
-25
3,527
-1,640
7,175
4,368
2,877
1,317
-3,630
-775
Effective Tax Rate (%)
- -
23.6
- -
22.75
22.86
21.39
21.6
- -
- -
Profit Margin (%)
- -
14.87
-6.22
25.83
16.1
9.32
3.26
-7.02
-1.53
Working Capital
9,832
11,144
24,362
29,627
23,582
6,218
-7,476
19,427
19,177
LT Debt
1,453
129
775
170
122
63
1,079
11,047
9,176
Total Equity
8,333
12,357
24,886
33,331
38,084
40,336
45,737
62,666
63,509
Return on Invested Capital (%)
- -
30.12
- -
13.62
6.36
5.39
5.07
- -
- -
Return on Capital (%)
- -
31.09
- -
23
10.35
7.98
5.1
- -
- -
Return on Common Equity (%)
- -
34.09
-8.81
24.71
12.31
7.37
3.22
-7.18
-1.45

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
213
2,235
2,271
LT Borrowings
10,750
8,750
8,750
LT Finance Leases
297
381
426
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
42
42
Market Capitalization
121,836
103,571
56,912

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
27,464
28,322
30,189
Cash, Cash Equivalents & STI
7,033
7,037
7,884
Accounts Receivable, Net
12,833
13,091
13,174
Inventories
5,963
6,196
7,104
Total Current Liabilities
8,038
10,072
11,012
Payables & Accruals
- -
- -
- -
ST Debt
213
2,235
2,271
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
20.9%
37.01%
Free Cash Flow
- -
-244.9%
-68.38%
Net Income, GAAP
- -
-208.14%
-375.72%
Sales/Revenue/Turnover
- -
15.12%
27.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,816
8,445
13,035
11,292
40,411
2025
12,824
12,984
13,421
12,477
51,706
2026
11,946
12,925
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15
7
-12
35.33
44
2025
21
-82
26.24
-64.63
-106
2026
2.33
20.49
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yoon-Seok Lee
Full Time Employees
29
Sector
Health technology
Industry
Medical specialties
Address
Seoul South Korea
IPO Date
Sep 21, 2018
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
WSI Co., Ltd. is a South Korea-based healthcare and medical technology company primarily engaged in the development, manufacture, and distribution of specialized medical devices, surgical biomaterials, and advanced medical solutions for spinal, orthopedic, and neurosurgical procedures. Founded in 2016 and headquartered in Seoul, South Korea, the company operates across key medical segments focusing on surgical hemostasis, spinal fusion, minimally invasive surgery, and medical robotics. Its core product and service offerings comprise surgical hemostatic agents and topical absorbable sealants, including flowable gelatin-thrombin matrix hemostats used for intraoperative bleeding control; anti-adhesion barriers and surgical wound care solutions designed to prevent postoperative tissue adhesion; spinal fixation and fusion systems, such as pedicle screws, cervical and lumbar interbody cages, and artificial disc implants; minimally invasive spinal endoscopy systems, radiofrequency ablation electrodes, and precision access instruments; bone graft substitutes, demineralized bone matrix materials, and synthetic bone void fillers; and specialized medical consumables supplied to general hospitals, university medical centers, and specialized surgical clinics throughout South Korea and international markets. In recent years, WSI Co., Ltd. has accelerated strategic growth initiatives by expanding into surgical robotics and diversifying its clinical portfolio. The company has entered into strategic partnerships and exclusive distribution agreements to commercialize robotic-assisted spinal surgery platforms and artificial intelligence-guided surgical navigation systems. In addition, WSI Co., Ltd. has completed acquisitions of medical distribution assets and established specialized subsidiaries to expand into women's healthcare, cardiovascular medical consumables, and regenerative biologics, while advancing global regulatory approvals to scale export operations across Asia-Pacific and overseas markets.